Advancing a class on top of statins
Investors & Media

Investor Overview

Gemphire is a clinical-stage biopharmaceutical company focused on developing and commercializing therapies for the treatment of dyslipidemia, a serious medical condition that increases the risk of life threatening cardiovascular disease. Dyslipidemia is generally characterized by an elevation of low-density lipoprotein cholesterol (LDL-C), or bad cholesterol, triglycerides, or fat in the blood, or both... More >>

NASDAQ | GEMP (Common Stock)

$1.36

 0.19 (12.26%)

High$1.54
Low$1.33
Volume907,922
Market Cap$19,355,946

08/15/18  4:00 p.m. ET

Data provided by Nasdaq. Minimum 15 minutes delayed.
Stock chart for: GEMP.O.  Currently trading at $1.36 with a 52 week high of $11.43 and a 52 week low of $0.83.

Gemphire Therapeutics Reports Second Quarter 2018 Financial Results and Provides Corporate Update

08/13/18

Read More

Gemphire Announces Termination of Phase 2a Clinical Trial of Gemcabene in Pediatric NAFLD

08/10/18

Read More

Gemphire Provides Update On Development of Gemcabene

08/06/18

Read More


There are currently no events scheduled.